LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported ...
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies ...
Mama Loves to Eat on MSN
4 common B12 deficiency signs - and what to eat instead
Vitamin B12 is one of those nutrients that quietly keeps your entire body running - and when it drops too low, the effects ...
Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the company to lose more than 40% of their value in pre-market trading. The news is ...
Mary Hall is a editor for Investopedia's Advisor Insights, in addition to being the editor of several books and doctoral papers. Mary received her bachelor's in English from Kent State University with ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Neurodegenerative disease profoundly affects structures and pathways responsible for memory, cognition, and higher-order ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results